Paul M Harari

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation
    P M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 49:427-33. 2001
  2. ncbi request reprint Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 58:976-83. 2004
  3. pmc Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells
    Sergio Benavente
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 0600, USA
    Clin Cancer Res 15:1585-92. 2009
  4. pmc Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 72:534-42. 2008
  5. ncbi request reprint Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792 0600, USA
    Int J Cancer 118:1041-50. 2006
  6. pmc Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers
    Shyhmin Huang
    Corresponding Author Paul M Harari, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, K4 336, 600 Highland Avenue, Madison, WI 53792 0600
    Mol Cancer Ther 12:2772-81. 2013
  7. pmc Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Cancer Biol Ther 8:696-703. 2009
  8. ncbi request reprint Modulation of radiation response by histone deacetylase inhibition
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 62:223-9. 2005
  9. ncbi request reprint Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Res 65:3328-35. 2005
  10. ncbi request reprint Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade
    Jing Li
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 62:1477-85. 2005

Detail Information

Publications80

  1. ncbi request reprint Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation
    P M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 49:427-33. 2001
    ....
  2. ncbi request reprint Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 58:976-83. 2004
    ..To highlight some of the preclinical data that examine the interaction of epidermal growth factor receptor (EGFR) inhibitors with radiotherapy and chemotherapy...
  3. pmc Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells
    Sergio Benavente
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 0600, USA
    Clin Cancer Res 15:1585-92. 2009
    ..Many tumors, however, eventually manifest resistance to treatment. Efforts to better understand the underlying mechanisms of acquired resistance to EGFR inhibitors, and potential strategies to overcome resistance, are greatly needed...
  4. pmc Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 72:534-42. 2008
    ..To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck squamous cell carcinoma and non-small-cell lung cancer cell lines and xenografts...
  5. ncbi request reprint Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792 0600, USA
    Int J Cancer 118:1041-50. 2006
    ....
  6. pmc Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers
    Shyhmin Huang
    Corresponding Author Paul M Harari, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, K4 336, 600 Highland Avenue, Madison, WI 53792 0600
    Mol Cancer Ther 12:2772-81. 2013
    ..The unique action mechanism of Sym004 warrants further investigation as a promising EGFR targeting agent combined with radiotherapy in cancer therapy...
  7. pmc Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Cancer Biol Ther 8:696-703. 2009
    ....
  8. ncbi request reprint Modulation of radiation response by histone deacetylase inhibition
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 62:223-9. 2005
    ..In this study, we examine the capacity of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) to modulate radiation response in human tumor cell lines and explore potential mechanisms underlying these interactions...
  9. ncbi request reprint Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Res 65:3328-35. 2005
    ..These data suggest that the erlotinib/radiation combination represents a strategy worthy of further examination in clinical trials...
  10. ncbi request reprint Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade
    Jing Li
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 62:1477-85. 2005
    ..These data suggest that molecular inhibition of VEGFR2 alone, and in combination with radiation, can enhance tumor response through molecular targeting of tumor vasculature...
  11. ncbi request reprint Insulin-like growth factor-I receptor signaling blockade combined with radiation
    Gregory W Allen
    Department of Human Oncology, School of Medicine and Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Res 67:1155-62. 2007
    ..In summary, these results validate IGF-IR signal transduction blockade as a promising strategy to improve radiation therapy efficacy in human tumors, forming a basis for future clinical trials...
  12. pmc Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors
    Tim J Kruser
    Department of Human Oncology, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Clin Cancer Res 16:3639-47. 2010
    ..In this report we examine the interaction between motesanib and radiation in vitro and in head and neck squamous cell carcinoma (HNSCC) xenograft models...
  13. pmc Enhanced radiation sensitivity in HPV-positive head and neck cancer
    Randall J Kimple
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, 3107 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Res 73:4791-800. 2013
    ..This issue is under active investigation in a series of clinical trials attempting to de-escalate radiation (and chemotherapy) in selected patients with HPV+ HNC in light of their favorable overall survival outcome...
  14. ncbi request reprint Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792 0600, USA
    Cancer Res 64:5355-62. 2004
    ..This approach suggests potential new strategies to maximize effective target inhibition, which may improve the therapeutic ratio for anti-EGFR-targeted therapies in developing clinical trials...
  15. pmc Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience
    Anne M Traynor
    Section of Hematology and Medical Oncology, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Head Neck 32:599-606. 2010
    ....
  16. pmc A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatments
    Leah K Schubert
    Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Int J Radiat Oncol Biol Phys 73:1260-9. 2009
    ..To assess patient setup corrections based on daily megavoltage CT (MVCT) imaging for four anatomic treatment sites treated on tomotherapy...
  17. ncbi request reprint Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade
    Shyh Min Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792 0600, USA
    Mol Cancer Ther 1:507-14. 2002
    ..Taken together, these results provide evidence that C225 can suppress tumor-induced neovascularization and metastasis in SCC of the head and neck...
  18. doi request reprint Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Cancer Res 73:824-33. 2013
    ....
  19. ncbi request reprint Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)
    Shyh Min Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer Res 62:4300-6. 2002
    ....
  20. ncbi request reprint EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
    Ranee Mehra
    Department of Human Oncology, University of Wisconsin School of Medicine, 600 Highland Avenue K4 336, Madison, WI 53792, USA
    Curr Oncol Rep 10:176-84. 2008
    ..These promising results have prompted further study of EGFR inhibitors with radiation and cytotoxic chemotherapy to further increase the benefit of treatment for SCCHN...
  21. pmc Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Semin Radiat Oncol 19:63-8. 2009
    ....
  22. ncbi request reprint Megavoltage computed tomography: an emerging tool for image-guided radiotherapy
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
    Am J Clin Oncol 30:617-23. 2007
    ..In this study, we assessed the image-quality, absorbed radiation doses, and clinical practicality of MVCT from our helical tomotherapy prototype unit...
  23. ncbi request reprint Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions
    Søren M Bentzen
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4 316 Clinical Sciences Center, Madison, WI 53792, USA
    Nat Clin Pract Oncol 4:172-80. 2007
    ..Further clinical progress in this field will require hypothesis-driven trials to ensure efficient identification of treatments with the most favorable risk:benefit ratio...
  24. ncbi request reprint Radiation combined with EGFR signal inhibitors: head and neck cancer focus
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, 53792, USA
    Semin Radiat Oncol 16:38-44. 2006
    ..Much remains to be learned regarding the rational integration of EGFR inhibitors into cancer treatment regimens as well as methods to optimize the selection of patients most likely to benefit from EGFR inhibitor strategies...
  25. doi request reprint Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
    David M Francis
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Clin Cancer Res 22:633-43. 2016
    ..Pan-HER represents a novel molecular targeted therapeutic composed of a mixture of six monoclonal antibodies against EGFR, HER2, and HER3...
  26. doi request reprint Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy
    Donald M Cannon
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Head Neck 36:1120-5. 2014
    ..However, the significance of prolonged RTT with concurrent chemotherapy is less clear...
  27. pmc Enhancement of radiation response with bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Exp Clin Cancer Res 31:37. 2012
    ..Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab...
  28. ncbi request reprint Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    Curr Probl Cancer 28:7-40. 2004
  29. ncbi request reprint Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison
    C Wesley Hodge
    Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:1032-41. 2007
    ....
  30. pmc Understanding resistance to EGFR inhibitors-impact on future treatment strategies
    Deric L Wheeler
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53705, USA
    Nat Rev Clin Oncol 7:493-507. 2010
    ..A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer...
  31. pmc Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies
    Andrew P Stein
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 53706
    Cancer Med 4:699-712. 2015
    ..Despite these promising initial results, this work requires additional preclinical validation, likely involving the use of patient-derived xenografts, prior to moving into the clinical realm for confirmation among patients with HNSCC. ..
  32. pmc p53 modulates acquired resistance to EGFR inhibitors and radiation
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Cancer Res 71:7071-9. 2011
    ....
  33. pmc Emphasizing conformal avoidance versus target definition for IMRT planning in head-and-neck cancer
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 77:950-8. 2010
    ..To describe a method for streamlining the process of elective nodal volume definition for head-and-neck (H&N) intensity-modulated radiotherapy (IMRT) planning...
  34. ncbi request reprint Intensity-modulated radiation therapy in the management of head and neck cancer
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
    Curr Opin Oncol 17:231-5. 2005
    ..This review updates recent advances regarding the use of this emerging technology...
  35. ncbi request reprint Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine, Madison 53792, USA
    Semin Radiat Oncol 12:21-6. 2002
    ..This report focuses primarily on the capacity of EGFR inhibitors to modulate cellular and overall tumor response to ionizing radiation...
  36. ncbi request reprint Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer
    Paul M Harari
    University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S25-7. 2007
    ....
  37. doi request reprint Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors
    Lauryn R Werner
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Mol Cancer Ther 14:1994-2003. 2015
    ..Taken together, these data identify the capacity of AMG 232 to augment radiation response across a variety of tumor types harboring functional p53...
  38. ncbi request reprint Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy
    James S Welsh
    Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, USA
    Technol Cancer Res Treat 5:465-79. 2006
    ....
  39. doi request reprint Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapy
    Mark J Been
    Department of Surgery, Division of Otolaryngology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Laryngoscope 118:1377-82. 2008
    ..The purpose of this study was to conduct an institutional review analyzing the correlation between tumor volume and locoregional control of oropharyngeal squamous cell cancer treated with primary radiotherapy...
  40. ncbi request reprint Anti-EGFR therapy update: clinical experience and adverse event insights
    Paul M Harari
    Department of Human Oncology, University of Wisconsin, Madison, Wisconsin 53792, USA
    Oncology (Williston Park) 20:3-4. 2006
  41. ncbi request reprint Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin Medical School, Madison, 53792 0600, USA
    Semin Radiat Oncol 16:59-64. 2006
    ..These approaches reviewed herein hold promise for improved radiation therapy efficacy and, ultimately, improved patient outcome...
  42. ncbi request reprint Parotidectomy: ten-year review of 237 cases at a single institution
    David C Upton
    Department of Surgery, Division of Otolaryngology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Otolaryngol Head Neck Surg 136:788-92. 2007
    ....
  43. ncbi request reprint Bridging gaps in multidisciplinary head and neck cancer care: nursing coordination and case management
    Peggy A Wiederholt
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S88-91. 2007
    ....
  44. doi request reprint Therapeutic selective neck dissection outcomes
    Peter M Shepard
    Department of Surgery, Otolaryngology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Otolaryngol Head Neck Surg 142:741-6. 2010
    ..To evaluate the effectiveness of selective neck dissection in patients with nodal metastases from head and neck squamous cell carcinoma...
  45. ncbi request reprint Biology of interactions: antiepidermal growth factor receptor agents
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Clin Oncol 25:4057-65. 2007
    ..Many questions remain to be answered, particularly with regard to how best combine EGFR inhibitors with conventional cancer therapies, and how to select those patients (tumors) most likely to benefit from EGFR inhibition strategies...
  46. pmc In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
    Zachary S Morris
    Department of Human Oncology, University of Wisconsin, Madison, Wisconsin
    Cancer Res 76:3929-41. 2016
    ..Cancer Res; 76(13); 3929-41. ©2016 AACR. ..
  47. doi request reprint Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers
    Chunrong Li
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Mol Cancer Ther 14:2049-59. 2015
    ..The dual EGFR/HER3-targeting action of MEHD7945A merits further investigation and clinical trial evaluation as a radiation sensitizer in cancer therapy...
  48. doi request reprint Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer
    Julian C Hong
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Int J Radiat Oncol Biol Phys 87:290-6. 2013
    ..We assessed whether more limited neck RT used for early-stage (T1-T2 N0) glottic cancer is associated with increased CVD risk, using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database...
  49. ncbi request reprint Radiation oncology advances: an introduction
    Søren M Bentzen
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Cancer Treat Res 139:1-4. 2008
  50. ncbi request reprint The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Medical School, University Hospital and Clinics, 600 Highland Avenue K4 332, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 61:779-88. 2005
    ..This study provides a detailed analysis regarding the potential impact of daily setup variations on the overall integrity of H&N IMRT...
  51. ncbi request reprint Precautions in the use of intensity-modulated radiation therapy
    James S Welsh
    Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Technol Cancer Res Treat 4:203-10. 2005
    ..Here we discuss some of the precautions worthy of consideration when using IMRT and how these might be addressed in routine practice...
  52. ncbi request reprint Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck
    Nadine P Connor
    Department of Otolaryngology Head and Neck Surgery, University of Wisconsin Medical School, and William S Middleton Memorial Veterans Hospital, Madison, WI 53792 7375, USA
    Int J Radiat Oncol Biol Phys 65:1051-62. 2006
    ..Head-and-neck radiotherapy is associated with significant morbidities. Our purpose was to document impact of morbidities by use of multiple objective measures and health-related quality of life (HR-QOL)...
  53. ncbi request reprint Clinical advancement of EGFR inhibitors in cancer therapy
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, Madison, USA
    Methods Mol Biol 327:189-202. 2006
    ..This chapter provides an overview of EGFR inhibitors and key clinical trial results that are helping to define a future role for these molecular agents in cancer treatment...
  54. ncbi request reprint Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules
    Jack F Fowler
    Department of Human Oncology K4 316, University of Wisconsin, 600 Highland Ave, Madison, WI 53792, USA
    Radiother Oncol 69:161-8. 2003
    ..To investigate whether a predictive estimate can be obtained for a 'tolerance level' of acute oral and pharyngeal mucosal reactions in patients receiving head and neck radiotherapy, using an objective set of dose and time data...
  55. ncbi request reprint Helical tomotherapy: an innovative technology and approach to radiation therapy
    James S Welsh
    Department of Human Oncology, University of Wisconsin, School of Medicine, 600 Highland Avenue, Madison, WI 53792, USA
    Technol Cancer Res Treat 1:311-6. 2002
    ..e "conformal avoidance", the counterpart of conformal radiation therapy. Based on radiobiological principles that exploit the physical advantages of helical tomotherapy, several dosimetric and clinical investigations are underway...
  56. ncbi request reprint Planned postradiotherapy neck dissection: Rationale and clinical outcomes
    Gregory K Sewall
    Division of Otolaryngology Head and Neck Surgery, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792, USA
    Laryngoscope 117:121-8. 2007
    ....
  57. pmc Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
    Zachary S Morris
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Cancer 122:2487-95. 2016
    ..Because of such mechanisms, it was hypothesized that these medications might affect the tumor response to neoadjuvant radiation in patients with rectal cancer...
  58. pmc Insulin growth factor 1 like receptor (IGF-1R)
    Gopal Iyer
    Department of Human Oncology and the University of Wisconsin School of Medicine and Public Health, University of Wisconsin Madison, Madison, 53792, USA
    BMC Cancer 16:773. 2016
    ..Prolonged exposure to cetuximab can result in cells acquiring resistance by a process that remains incompletely understood...
  59. doi request reprint Incidental Parotid Neoplasms: Pathology and Prevalence
    Christopher J Britt
    Division of Otolaryngology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Otolaryngol Head Neck Surg 153:566-8. 2015
    ..To better characterize parotid masses incidentally identified on imaging...
  60. pmc Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems
    Zachary S Morris
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States
    Radiother Oncol 116:504-9. 2015
    ..Here we describe the first preclinical studies of this diapeutic molecule in head and neck cancer (HNC) models...
  61. pmc Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts
    Randall J Kimple
    Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA
    Clin Cancer Res 19:855-64. 2013
    ....
  62. pmc Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin Carbone Cancer Center K4 B100 CSC, 600 Highland Avenue, Madison, WI 53792
    Technol Cancer Res Treat 12:383-9. 2013
    ....
  63. ncbi request reprint Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 10:428-32. 2004
  64. ncbi request reprint Parotid area lymph node metastases from cutaneous squamous cell carcinoma: implications for diagnosis, treatment, and prognosis
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Hospital and Clinics, 600 Highland Avenue K4 332, Madison, WI 53792, USA
    Head Neck 27:851-6. 2005
    ..Parotid area lymph node metastasis from primary scalp and facial cutaneous cancers is a poorly recognized clinical entity partly because of the long time lapse between the index lesion and regional spread...
  65. doi request reprint Selective omission of level V nodal coverage for patients with oropharyngeal cancer: Clinical validation of intensity-modulated radiotherapy experience and dosimetric significance
    Pranshu Mohindra
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Head Neck 38:499-505. 2016
    ..We sought to validate the consensus recommendation and assess dosimetric significance of selective omission of nodal level V from intensity-modulated radiotherapy (IMRT) clinical target volume (CTV) for oropharyngeal cancer...
  66. doi request reprint Patient and tumor characteristics predictive of primary parotid gland malignancy: A 20-year experience at the University of Wisconsin
    Andrew P Stein
    Department of Surgery, Division of Otolaryngology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA
    Am J Otolaryngol 36:429-34. 2015
    ..To identify patient and tumor characteristics predictive of primary parotid malignancy...
  67. ncbi request reprint Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center and School of Medicine, Madison, WI 53792, USA
    Semin Radiat Oncol 13:3-12. 2003
    ..However, we lack randomized trials that directly compare operative versus nonoperative treatment approaches and thus have consciously neglected review of the surgical series for purposes of this article...
  68. pmc Is radiation dose reduction the right answer for HPV-positive head and neck cancer?
    Randall J Kimple
    Department of Human Oncology, University of Wisconsin Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA Electronic address
    Oral Oncol 50:560-4. 2014
    ....
  69. ncbi request reprint The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium
    Paul M Harari
    University of Wisconsin, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S1-3. 2007
  70. ncbi request reprint Cetuximab (Imclone/Merck/Bristol-Myers Squibb)
    Merrill S Kies
    University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Curr Opin Investig Drugs 3:1092-100. 2002
    ..In May 2002, Lehman Brothers predicted global peak sales of US $2 billion [454652], while in the same month, Bear Stearns estimated that sales for Merck KGaA would reach 285 million Euros in 2007 [453500]...
  71. ncbi request reprint Clinical application of EGFR inhibitors in head and neck squamous cell cancer
    Igor Astsaturov
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Cancer Treat Res 139:135-52. 2008
  72. ncbi request reprint Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
    Desmond Curran
    Omega Research, Dublin, Ireland
    J Clin Oncol 25:2191-7. 2007
    ..In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab...
  73. doi request reprint Beware the swing and a miss: baseball precautions for conformal radiotherapy
    Paul M Harari
    Int J Radiat Oncol Biol Phys 70:657-9. 2008
  74. ncbi request reprint EGFR-targeting monoclonal antibodies in head and neck cancer
    Igor Astsaturov
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Curr Cancer Drug Targets 6:691-710. 2006
    ....
  75. pmc Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
    Christine H Chung
    Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S67-78. 2007
    ..In this position paper we outline strategic plans to further promote translational research within the framework of the RTOG...
  76. ncbi request reprint Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  77. ncbi request reprint Augmentation of radiation response with the vascular targeting agent ZD6126
    Tien Hoang
    Hematology Oncology Division, Ohio State University College of Medicine, Columbus, OH, USA
    Int J Radiat Oncol Biol Phys 64:1458-65. 2006
    ..The overall hypothesis was that simultaneous targeting of tumor cells (radiation) and tumor vasculature (ZD6126) might enhance tumor cell killing...
  78. ncbi request reprint Biologic basis for combining drugs with radiation
    George D Wilson
    Department of Radiation Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Semin Radiat Oncol 16:2-9. 2006
    ....
  79. ncbi request reprint ACCO: ASCO core curriculum outline
    Hyman B Muss
    Education, Science and Career Development, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 23:2049-77. 2005
  80. ncbi request reprint Introduction
    Paul M Harari
    Semin Radiat Oncol 16:1. 2006